Supreme Court takes up drug company dispute

The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment.

The justices agreed Monday to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug Copaxone.

The appeals court ruling would allow rivals Mylan Inc., Momenta Pharmaceuticals Inc. and Sandoz, Inc., to start selling generic versions of the drug later this year, after the remaining patents on the drug expire.

A had earlier ruled in Teva's favor and upheld the patents. Teva says the Federal Circuit should have deferred to factual findings made in the district court.

The justices will hear the case in the fall.

Related Stories

Teva says US is investigating Copaxone marketing

date Feb 10, 2014

Teva Pharmaceutical Industries said Monday the federal government is investigating its marketing of its multiple sclerosis drug Copaxone and Parkinson's disease treatment Azilect.

Court Denies Vonage Bid for Patent Case Retrial

date May 04, 2007

A U.S. appeals court denies a request by Internet phone company Vonage Holdings that it order a retrial in the patent infringement case brought against it by Verizon Communications.

Recommended for you

Joint search for new antibiotics

date 2 hours ago

The WHO has identified antibiotic resistance as one of the three biggest threats to human health. Without new antibiotics, we risk returning to a situation in which every infection is life-threatening. The ...

Mylan rebuffs Teva again; calls bid low, insincere

date 23 hours ago

Generic drug company Mylan rejected for the second time Monday a $40.1 billion takeover offer from Israeli pharmaceutical power Teva, just days after Mylan's own bid for rival Perrigo was rebuffed.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.